Publications
Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Gunn A, Haas N, Johnson M, Kapur P, King J, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Sweis R, Zibelman M, Schonfeld R, Stein M, Gurski LA. NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024. Journal of the National Comprehensive Cancer Network : JNCCN. 2024. PMID: 38394781
Daniel H Kwon, Lauren Trihy, Eliza Hearst, Nika Darvish, Gurleen Kaur, Samantha Nesheiwat, Hala Borno, Rohit Bose, Jonathan Chou, Ivan de Kouchkovsky, Arpita Desai, Kelly N. Fitzgerald, Lawrence Fong, Terence W. Friedlander, Vadim S Koshkin, Eric J. Small, Rahul Raj Aggarwal, Jeffrey Belkora. Implementing consultation audio recording applications to improve informed decision-making (IDM) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) eligible for docetaxel. Journal of Clinical Oncology. 2024. PMID:
Zussman JW, Ma JY, Bindman JG, Cornes S, Davis JA, Brondfield S. Identifying Strategies for the Use of Gender and Sex Language in Clinical One-Liners. LGBT health. 2024. PMID: 38301142
Kelley RK. Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular Carcinoma. Gastroenterology & hepatology. 2024. PMID: 38414909
Vadim S Koshkin, Tanya Jindal, Jun Yan He, Li Zhang, Celine N. Galang, Divya Natesan, Vipul Kumar, Xiaolin Zhu, Jonathan Chou, Rahul Raj Aggarwal, Eric J. Small, Maxwell Meng, Sima P. Porten, David Yoonsuk Oh, Lawrence Fong, Terence W. Friedlander. Efficacy outcomes and biomarker analysis from phase II trial of escalating doses of neoadjuvant atezolizumab in patients with muscle-invasive urothelial carcinoma ineligible for cisplatin-based chemotherapy. Journal of Clinical Oncology. 2024. PMID:
Wu C, Mulakaluri A, Chaurasia P, Suryanarayana S, Singh A, Krauss N, Tahir P, Elder C, Puthiyedath R, Dhruva A. A scoping review of Ayurvedic rasayana adaptogens in oncology. Journal of Ayurveda and integrative medicine. 2024. PMID: 38301299
DeBoer RJ, Ho A, Mutoniwase E, Nguyen C, Umutesi G, Bigirimana JB, Nsabimana N, Van Loon K, Shulman LN, Triedman SA, Cubaka VK, Shyirambere C. Ethical dilemmas in prioritizing patients for scarce radiotherapy resources. BMC medical ethics. 2024. PMID: 38297294
DeBoer RJ, Ho A, Mutoniwase E, Nguyen C, Umutesi G, Bigirimana JB, Nsabimana N, Van Loon K, Shulman LN, Triedman SA, Cubaka VK, Shyirambere C. Ethical dilemmas in prioritizing patients for scarce radiotherapy resources. BMC medical ethics. 2024. PMID: 38297294
Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, Chuah C, DeAngelo DJ, Hochhaus A, Lipton JH, Mauro M, Nicolini F, Pinilla-Ibarz J, Rosti G, Rousselot P, Shah NP, Talpaz M, Vorog A, Ren X, Kantarjian H. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024. PMID: 38287132
Li W, Garcia-Rivera EM, Mitchell DC, Chick JM, Maetani M, Knapp JM, Matthews GM, Shirasaki R, de Matos Simoes R, Viswanathan V, Pulice JL, Rees MG, Roth JA, Gygi SP, Mitsiades CS, Kadoch C, Schreiber SL, Ostrem JML. Highly specific intracellular ubiquitination of a small molecule. bioRxiv : the preprint server for biology. 2024. PMID: 38328167
Bobba KN, Bidkar AP, Wadhwa A, Meher N, Drona S, Sorlin AM, Bidlingmaier S, Zhang L, Wilson DM, Chan E, Greenland NY, Aggarwal R, VanBrocklin HF, He J, Chou J, Seo Y, Liu B, Flavell RR. Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5. Theranostics. 2024. PMID: 38389832
Bobba KN, Bidkar AP, Wadhwa A, Meher N, Drona S, Sorlin AM, Bidlingmaier S, Zhang L, Wilson DM, Chan E, Greenland NY, Aggarwal R, VanBrocklin HF, He J, Chou J, Seo Y, Liu B, Flavell RR. Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5. Theranostics. 2024. PMID: 38389832
Bobba KN, Bidkar AP, Wadhwa A, Meher N, Drona S, Sorlin AM, Bidlingmaier S, Zhang L, Wilson DM, Chan E, Greenland NY, Aggarwal R, VanBrocklin HF, He J, Chou J, Seo Y, Liu B, Flavell RR. Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5. Theranostics. 2024. PMID: 38389832
Chang H, Marquez Garcia J, Chen BK, Kim DM, Cheng ML, Liu EV, Yang H, Zhang L, Sinha M, Cheung A, Kwek SS, Chow ED, Bridge M, Aggarwal RR, Friedlander TW, Small EJ, Anderson M, Fong L. Immune modulation with RANKL blockade through denosumab treatment in patients with cancer. Cancer immunology research. 2024. PMID: 38276989
Chang H, Marquez Garcia J, Chen BK, Kim DM, Cheng ML, Liu EV, Yang H, Zhang L, Sinha M, Cheung A, Kwek SS, Chow ED, Bridge M, Aggarwal RR, Friedlander TW, Small EJ, Anderson M, Fong L. Immune modulation with RANKL blockade through denosumab treatment in patients with cancer. Cancer immunology research. 2024. PMID: 38276989
Chen JJ, Zhu I, Patel A, Krings G, Chen YY, Yuen F, Mukhtar RA, Melisko M, Singer L, Park CC, Prionas ND. Management of Concurrent Malignant Phyllodes Tumor and Invasive Breast Carcinoma. Advances in radiation oncology. 2024. PMID: 38550370
Chang H, Marquez Garcia J, Chen BK, Kim DM, Cheng ML, Liu EV, Yang H, Zhang L, Sinha M, Cheung A, Kwek SS, Chow ED, Bridge M, Aggarwal RR, Friedlander TW, Small EJ, Anderson M, Fong L. Immune modulation with RANKL blockade through denosumab treatment in patients with cancer. Cancer immunology research. 2024. PMID: 38276989
Chang H, Marquez Garcia J, Chen BK, Kim DM, Cheng ML, Liu EV, Yang H, Zhang L, Sinha M, Cheung A, Kwek SS, Chow ED, Bridge M, Aggarwal RR, Friedlander TW, Small EJ, Anderson M, Fong L. Immune modulation with RANKL blockade through denosumab treatment in patients with cancer. Cancer immunology research. 2024. PMID: 38276989
Chang H, Marquez Garcia J, Chen BK, Kim DM, Cheng ML, Liu EV, Yang H, Zhang L, Sinha M, Cheung A, Kwek SS, Chow ED, Bridge M, Aggarwal RR, Friedlander TW, Small EJ, Anderson M, Fong L. Immune modulation with RANKL blockade through denosumab treatment in patients with cancer. Cancer immunology research. 2024. PMID: 38276989
Chang H, Marquez Garcia J, Chen BK, Kim DM, Cheng ML, Liu EV, Yang H, Zhang L, Sinha M, Cheung A, Kwek SS, Chow ED, Bridge M, Aggarwal RR, Friedlander TW, Small EJ, Anderson M, Fong L. Immune modulation with RANKL blockade through denosumab treatment in patients with cancer. Cancer immunology research. 2024. PMID: 38276989